Clinical Trial Update: Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer [Phase 1]

View source ↗

Summary

Clinical trial update for intrathecal pertuzumab and trastuzumab in HER2-positive breast cancer with brain metastases; this Phase 1 study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Breast Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Kimberly Blackwell | Conditions: HER2 Positive Untreated Metastatic Breast Cancer, Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer | Phase 1 | Status: TERMINATED